AIDS Research and Human Retroviruses · 2017 · 67 citations · 30 references
Life SciencesImmunologyInfectious DiseasesCell TherapyClinical ImmunologyImmunotherapyAntiretroviral TherapyAntiviral ImmunityAntiviral TherapyCell-based ImmunotherapyCell-mediated ImmunityT Cell ActivationAntigen-specific T Cell ResponsesAntiviral T Cell ResponsesCd4 T Cell ActivationHiv Envelope Glycoprotein AntigensImmune Reconstitution After Antiretroviral TherapyImmune Response AssessmentT-cell Immune ResponsesViral Immune Responses
AGS-004 consists of matured autologous dendritic cells co-electroporated with in vitro transcribed RNA encoding autologous HIV antigens. In an open-label, single arm sub-study of AGS-004-003, AGS-004 was administered monthly to suppressed participants who started antiretroviral therapy (ART) during acute HIV infection. HIV-1 specific T cell responses were measured by multicolor flow cytometry after 3–4 doses. The frequency of resting CD4 + T-cell infection (RCI) was measured by quantitative viral outgrowth assay. Participants demonstrating increased immune response postvaccination were eligible for analytic treatment interruption (ATI). AGS-004 induced a positive immune response defined as ≥2-fold increase from baseline in the number of multifunctional HIV-1 specific CD28 + /CD45RA − CD8 + effector/memory cytoxic T-lymphocytes (CTLs) in all six participants. All participants underwent ATI with rebound viremia at a median of 29 days. Immune correlates between time to viral rebound and the induction of effector CTLs were determined. Baseline RCI was low in most participants (0.043–0.767 IUPM). One participant had a >2-fold decrease (0.179–0.067 infectious units per million [IUPM]) in RCI at week 10. One participant with the lowest RCI had the longest ATI. AGS-004 dendritic cell administration increased multifunctional HIV-specific CD28 + /CD45RA − CD8 + memory T cell responses in all participants, but did not permit sustained ART interruption. However, greater expansion of CD28 − /CCR7 − /CD45RA − CD8 + effector T cell responses correlated with a longer time to viral rebound. AGS-004 may be a useful tool to augment immune responses in the setting of latency reversal and eradication strategies.
30
Richard A. Koup, Jeffrey T. Safrit, Yaming Cao et al. · Journal of Virology · 1994 · 2.5K citations · Full text
Brandon F. Keele, Elena E. Giorgi, Jesus F. Salazar-Gonzalez et al. · Proceedings of the National Academy of Sciences · 2008 · 1.9K citations · Full text
Life Sciences, Evolutionary Biology, Infectious Diseases +17
Persephone Borrow, Hanna Lewicki, Beatrice H. Hahn et al. · Journal of Virology · 1994 · 1.9K citations · Full text
Immune control of HIV-1 after early treatment of acute infection
Eric Rosenberg, Marcus Altfeld, Samuel Poon et al. · Nature · 2000 · 998 citations
Asier Sáez‐Cirión, Charline Bacchus, Laurent Hocqueloux et al. · PLoS Pathogens · 2013 · 998 citations · Full text